HIMS
Hims Hers Health Inc
NYSE: HIMS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$26.82
-7.10% today
Updated 2026-06-12
Market cap
$6.21B
P/E ratio
—
P/S ratio
2.62x
EPS (TTM)
$-0.09
Dividend yield
—
52W range
$14 – $70
Volume
27.3M
Hims Hers Health Inc (HIMS) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed HIMS price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$26.82
Today
Analyst consensus
$29.37
+9.51% · 12M
2030 Base
$117.83
+339.34% future
NPV today
$55.37
@ 18% WACC
17 analysts:
4 Buy11 Hold2 Sell
Management guidance
Management has not provided explicit 2026-2030 revenue targets in recent earnings calls. However, the company is pursuing aggressive international expansion (Eucalyptus acquisition in Australia, entry into Canada with generic semaglutide), $350M convertible offering explicitly for expansion and AI-driven platform investment, and expansion into new therapeutic categories (GLP-1, menopause care). Implied guidance suggests 20%+ near-term growth with acceleration potential from new markets and categories.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
HIMS · Hims Hers Health Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$57.58
NPV today: $27.06
Base case (2030)
$117.83
NPV today: $55.37
Bull case (2030)
$147.96
NPV today: $69.53
WallStSmart.com
HIMS financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $3.3B | $4.2B | $5.2B | $6.2B | $7.1B |
| Revenue growth | 59.0% | 38.3% | 28.6% | 24.1% | 19.0% | 15.5% |
| Net margin | — | 2.0% | 3.4% | 4.4% | 5.1% | 5.7% |
| EPS | $0.87 | $0.28 | $0.62 | $0.98 | $1.35 | $1.72 |
| Diluted shares | — | 226M | 229M | 232M | 235M | 237M |
| Net debt | — | $679.36M | $670.47M | $659.44M | $646.31M | $631.14M |
| P/S multiple | — | 2.0x | 3.0x | 3.0x | 4.0x | 4.0x |
| Implied price (base) | — | $25.71 | $51.75 | $64.24 | $102.58 | $117.83 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $7.1B | $7.1B | $7.1B |
| P/S multiple | 2.0x | 4.0x | 5.0x |
| Diluted shares | 237M | 237M | 237M |
| Net debt | $631.14M | $631.14M | $631.14M |
| Implied P/E † | 34x | 69x | 86x |
| 2030 Price | $57.58 | $117.83 | $147.96 |
| NPV @ 18% | $27.06 | $55.37 | $69.53 |
† Implied P/E: Multiples remain elevated across all three scenarios because HIMS is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $117.83 base case
HIMS catalysts and risks
Growth catalysts
+ Eucalyptus acquisition closure and Australian market monetization (2026-2027)
+ GLP-1 and weight-loss drug category expansion; Novo Nordisk partnership maturation and LillyDirect distribution model scaling
+ International expansion (Canada, UK, Europe) with localized offerings and generic drug access
+ AI-driven platform improvements and cost efficiency gains from fulfillment infrastructure investment ($350M capex plan)
+ Market consolidation in telehealth; Hims positioning as 'Netflix of pharma' with closed-loop data ecosystem
Key risks
- Q1 2026 earnings miss (revenue +4% QoQ, below guidance); profitability pressure and adjusted EBITDA down 51% YoY suggests margin compression despite growth
- Competitive pressure from Amazon Pharmacy (weight management launch), GoodRx, traditional pharmacies, and Eli Lilly's LillyDirect direct-to-consumer model reducing Hims' GLP-1 margin advantage
- Regulatory risk: FDA restrictions on compounded GLP-1 drugs, mail-order abortion pill restrictions, state-level telehealth licensing; patent expirations (Novo Nordisk Ozempic/Wegovy) increase generic competition
- Integration execution risk on Eucalyptus acquisition and international expansion; high debt load ($5.85B EV, 2.54x debt/equity) limits financial flexibility post-$350M convertible issuance
- Customer concentration risk: dependency on GLP-1 market as % of revenue; slowing growth trajectory (59% CAGR 2021-2025 decelerating to 24.8% projected 2026 growth) suggests market saturation in core US market
Methodology · Hims Hers Health Inc 2030 stock forecast model
Hims Hers Health Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 17 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (6% cumulative for HIMS by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($631.14M by 2030) |
| 3. Time value | NPV calculated using 18% WACC (CAPM: beta 2.423) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 4.0x / bull 5.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 22, 2026.
HIMS price target FAQ
What is the HIMS price target for 2030?
WallStSmart's Hims Hers Health Inc 2030 base case is $117.83 per share, with a bull case of $147.96 and bear case of $57.58. The NPV of the base case discounted to today at 18% WACC is $55.37.
How is the Hims Hers Health Inc 2030 stock forecast calculated?
The HIMS 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the HIMS price target account for dilution?
Hims Hers Health Inc is projected to grow diluted share count from 223M to 237M by 2030 (a 6% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 6%.
What is the analyst consensus on HIMS stock?
17 analysts cover HIMS with an average 12-month price target of $29.37. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.